The estimated Net Worth of Terri B Sebree is at least $1.85 Milion dollars as of 12 September 2023. Ms. Sebree owns over 12,401 units of Zynerba Pharmaceuticals Inc stock worth over $775,113 and over the last 9 years she sold ZYNE stock worth over $40,399. In addition, she makes $1,038,880 as President at Zynerba Pharmaceuticals Inc.
Terri has made over 4 trades of the Zynerba Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she sold 12,401 units of ZYNE stock worth $16,493 on 12 September 2023.
The largest trade she's ever made was selling 24,661 units of Zynerba Pharmaceuticals Inc stock on 23 January 2023 worth over $14,797. On average, Terri trades about 3,510 units every 133 days since 2015. As of 12 September 2023 she still owns at least 596,241 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Ms. Sebree stock trades at the bottom of the page.
Terri B. Sebree serves as President of the Company. Ms. Sebree served as our business consultant from May 2014 to October 2014. Ms. Sebree has more than 30 years of executive, development and operational experience in the pharmaceutical industry, particularly in central nervous system product development including epilepsy and pain. Ms. Sebree founded and served as president of NuPathe, a specialty pharmaceutical company, from February 2005 until April 2014, where she led the effort to develop, achieve regulatory approval for and complete manufacturing of the company's lead product, Zecuity, a transdermal patch for migraines. Prior to founding NuPathe, Ms. Sebree served as senior vice president, development of Auxilium, a specialty pharmaceutical company, where she led the development and approval program of Testim, a testosterone gel. Prior to joining Auxilium, Ms. Sebree served as executive vice president, U.S. Operations at IBAH, Inc., a contract research organization. Prior to that, Ms. Sebree served in a variety of management roles with Abbott Laboratories Inc., a global healthcare company, for over nine years. Ms. Sebree currently serves on the board of directors of Serodus ASA, a private Scandinavian pharmaceutical company. Ms. Sebree holds a B.S. from Texas A&M University.
As the President of Zynerba Pharmaceuticals Inc, the total compensation of Terri Sebree at Zynerba Pharmaceuticals Inc is $1,038,880. There are 1 executives at Zynerba Pharmaceuticals Inc getting paid more, with Armando Anido having the highest compensation of $1,369,570.
Terri Sebree is 62, she's been the President of Zynerba Pharmaceuticals Inc since 2014. There are 7 older and 6 younger executives at Zynerba Pharmaceuticals Inc. The oldest executive at Zynerba Pharmaceuticals Inc is Daniel Kisner, 72, who is the Independent Director.
Terri's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici oraz Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include: